Based on the key indicators related to Virax Biolabs' liquidity, profitability, solvency, and operating efficiency, Virax Biolabs Group is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Virax Biolabs' Capital Stock is fairly stable compared to the past year. Net Working Capital is likely to rise to about 5.1 M in 2025, whereas Total Assets are likely to drop slightly above 3.4 M in 2025. Key indicators impacting Virax Biolabs' financial strength include:
The essential information of the day-to-day investment outlook for Virax Biolabs includes many different criteria found on its balance sheet. An individual investor should monitor Virax Biolabs' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Virax Biolabs.
Please note, the imprecision that can be found in Virax Biolabs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virax Biolabs Group. Check Virax Biolabs' Beneish M Score to see the likelihood of Virax Biolabs' management manipulating its earnings.
Virax Biolabs Stock Summary
Virax Biolabs competes with Revelation Biosciences, Kiora Pharmaceuticals, Quoin Pharmaceuticals, Cardio Diagnostics, and Allarity Therapeutics. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. Virax Biolabs is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Virax Biolabs Group. It measures of how well Virax is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Virax Biolabs brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Virax had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Virax Biolabs has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Virax Biolabs's current stock value. Our valuation model uses many indicators to compare Virax Biolabs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virax Biolabs competition to find correlations between indicators driving Virax Biolabs's intrinsic value. More Info.
Virax Biolabs Group is rated second in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Virax Biolabs' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Virax Biolabs' earnings, one of the primary drivers of an investment's value.
Virax Biolabs Group Systematic Risk
Virax Biolabs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Virax Biolabs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Virax Biolabs Group correlated with the market. If Beta is less than 0 Virax Biolabs generally moves in the opposite direction as compared to the market. If Virax Biolabs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Virax Biolabs Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Virax Biolabs is generally in the same direction as the market. If Beta > 1 Virax Biolabs moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Virax Biolabs Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Virax Biolabs' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Virax Biolabs growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Virax Biolabs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Virax Biolabs Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of Virax Biolabs Group based on widely used predictive technical indicators. In general, we focus on analyzing Virax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Virax Biolabs's daily price indicators and compare them against related drivers.
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.